About us

Sean brings more than 25 years of experience in the biopharmaceutical industry, spanning early development through to launch and commercial success. At GSK, he led cross-functional teams that delivered two of the industry’s most successful vaccines, Shingrix and Arexvy, and contributed to reshaping treatment approaches in diabetes and cardiovascular disease.

Post GSK, he has continued to hold senior leadership roles, most recently as Chief Operating Officer at HilleVax, where he prepared the company for Phase 3 development and commercialization of its norovirus vaccine platform.

At Denteric, he applies this same expertise in strategy, execution and team leadership to advance its pipeline.

MBA St. Joseph’s University (Philadelphia), BSc (Accounting) Queen’s University Belfast, Certificate in Executive Leadership Wharton School, University of Pennsylvania.

An accomplished life sciences executive with more than 30 years experience, Larisa brings cross-functional expertise from ASX, NASDAQ, academia, not for profit and startup companies.  Larisa spent 14 years at ASX listed Immutep and excels in strategically aligning vaccine research, clinical trials, manufacturing, and commercialisation.

An active contributor to advancing education, she supports aspiring students, scientists, and women entrepreneurs through her involvement with the Life Science Springboard program, RMIT Biomedical Science Industry Advisory Committee and Central Pharmacy Logistics.

Bachelor of Science (Honours), MBA La Trobe University, Australian Institute of Company Directors.

.

With over 30 years’ experience in vaccine clinical development, in both the prophylactic and therapeutic settings,Paul has held pharmaceutical and biotechnology roles in the US, UK and Australia. This included 10 years at Pfizer, where he was Head of Cellular Immunology within the Vaccines Research Group and project leader for their VBIR cancer vaccine program. Prior to Denteric his recent focus had been in the field of oncology, with positions at Silverback Therapeutics, PsiOxus Therapeutics (now Akamis Bio), and Gritstone Bio. 

PhD in Clinical Medicine from the University of Oxford (UK).

Michal brings 15 years of research experience and strong commercial acumen to his role at Denteric. Before joining the company, he was a postdoctoral scientist at WEHI and Imperial College London, completed an internship with WEHI’s Business Development Office, and the Bridge Program. His fellowships include the Innovation Fellowship with Israeli VC fund aMoon, as well as awards from Boehringer Ingelheim Fonds, EMBO, and the Wellcome Trust.

At Denteric, Michal oversees the delivery of preclinical and clinical R&D programs, aligning scientific innovation with the company’s long-term commercial goals. He is passionate about translating scientific discoveries into therapies that save and improve lives.

​PhD in Molecular Biology from the University of Cambridge (UK), MBA from the Melbourne Business School.

Mike has over 35 years’ experience in the Australian biotechnology industry, with extensive experience working with numerous Contract Manufacturing Organisations overseas and locally in all facets of translational CMC from concept through to Phase 3 studies and drafting BLA submissions. In the process he has successfully guided the manufacture of numerous biologics through to Phase 1/2/3 clinical trials, including oversight of nonclinical programs, as well as associated regulatory interactions in North America, Europe and Australia. He has also directed the development of numerous in vitro diagnostic products through to the market over 19 years at Agen Biomedical. He has worked in senior positions at Opthea Ltd, as COO of Q-Gen, and other start-ups.

PhD in biotechnology QUT, BSc (Chem) UTS.

Cassandra is a biotechnology professional in the pharmaceutical drug discovery field, bringing expertise in the development of novel therapeutic agents alongside corporate and R&D program management to support translational science. During her PhD, she achieved the distinction of having her work featured on the front cover of ChemMedChem and included in its Special Collection on Cancer Research (2020 Hot Topic Series), a recognition of both scientific impact and innovation.

She supports the operations at Denteric, with responsibilities spanning financial reporting, compliance, and governance management. Concurrent to her role at Denteric, Cassandra also serves as Head of Operations at Cincera Therapeutics and as a Research Affiliate with the Monash Institute of Pharmaceutical Sciences (MIPS).

PhD in Medicinal Chemistry from Monash University.

Rob combines 15 years of entrepreneurial experience as a co-founder of multiple biotechnology companies and as a Venture Partner with Frazier Life Sciences with more than 25 years as a physician, scientist and biotechnology leader.  Formerly the Chair and CEO of HilleVax, a Frazier backed vaccine company, Rob led the development of a prophylactic vaccine for norovirus infections. Prior to Hillevax, Rob was the Chief Scientific Officer then Global Head of Business Development at Celgene up to the acquisition of Celgene by Bristol-Myers Squibb in 2019. Previous positions include CEO of VentiRx (a company he co-founded that was acquired by Celgene), Chief Medical Officer from Dendreon (acquired by Valeant Pharmaceucticals)  and Vice President of Medical Genetics at Corixa (a company acquired by Glaxo Smith Kline). He currently serves on the public boards of Recursion Pharmaceuticals, Adaptive Biotechnologies, ATAI and on the private boards of Cajal Therapeutics, Vesto Therapeutics, and Amandala Neurosciences. 

His prior academic positions include Assistant Professor at Harvard Medicals School and Associate Physician at Brigham and Women’s Hospital in Boston and Clinical Professor of Medical Genetics at the University of Washington School of Medicine.

PhD from the Salk Institute and MD at UCLA.

Patrick brings more than 35 years of global biopharmaceutical experience, including nearly three decades at GSK, where he shaped vaccine strategy, led business units across multiple geographies, and delivered major product launches.

As Global Head of Vaccines Commercial Strategy, he guided portfolio and pipeline decisions, oversaw the worldwide expansion of Shingrix, and led launch planning for RSV vaccines. He also served as Country President in France and Australia and led the U.S. Vaccines Business Unit, where he led the Shingrix and Bexsero launches that saw them secure the #1 position in the U.S. vaccines market.

Patrick has also served on key industry boards, including US Bio Vaccines Policy, Medicines Australia and France Bio-Pharma (LEEM). Originally from Montreal, he is driven by a passion for improving lives through innovative medicines and vaccines.

Anne-Laure possesses extensive academic and commercial research experience.  As a research scientist in academic institutions in France (Institut Pasteur, Inserm) and Singapore (A*STAR), as a staff scientist at Flamel Technologies in France (now Avadel Pharmaceuticals) and within the global Vaccines business unit at GlaxoSmithKline (GSK), in Belgium. 

During her time at GSK, she transitioned from Research and Development to Business Development and Licensing. Since then, she’s established a track record in successful technology transfer and collaborative projects with emphasis on early-stage assets (discovery / preclinical to phase I/II).

PhD in Immunology from INAPG (now AgroParisTech) at Institut Pasteur in Paris, France; Global Executive MBA from IE Business School in Madrid, Spain.

Andrew is Chief Scientific Officer at CSL, responsible for five therapeutic areas and three strategic platforms: plasma fractionation, recombinant protein technology and cell & gene therapy.  In his role, Andrew provides overarching scientific leadership at CSL and is directly responsible for its large global effort focused on the discovery of new medicines to treat rare and serious human disease.

Prior to CSL his appointments included CEO of ASX listed Zenyth Therapeutics (formerly Amrad Corporation) and an appointment at the Centre for Animal Biotechnology in the Faculty of Veterinary Science, University of Melbourne, where he founded and led a research group focused on basic and applied aspects of cytokine biology.  Andrew is an honourary Associate Professor at the University of Melbourne.

PhD in Immunology from The University of Melbourne.

Chris is a Partner at Brandon Capital, Australia’s largest life-science Venture Capital firm, who manage the Medical Research Commercialisation Fund (MRCF). He currently sits on the boards of several drug and medical device companies and before joining Brandon Capital, Chris was formerly a Business Development Manager with CSL. 

PhD from Walter Elisa Hall Institute, Australia; MBA from University of Cambridge, U.K.

Michael Wilson is the Senior Vice President, Head of Global Research at CSL. He is also an Honorary Senior Fellow at the University of Melbourne.  Michael has more than 25 years’ experience in drug discovery and development in the pharmaceutical and biotech industry in a range of clinical indications including rare diseases such as haemophilia and HAE as well as airway diseases.

Prior to CSL, Michael worked at GSK. He also worked in the UK as an academic scientist, at Cancer Research UK and the University of Cambridge.

PhD Recombinant Protein Vaccines from the University of Melbourne, MBA from the University of Warwick.

Sean brings more than 25 years of experience in the biopharmaceutical industry, spanning early development through to launch and commercial success. At GSK, he led cross-functional teams that delivered two of the industry’s most successful vaccines, Shingrix and Arexvy, and contributed to reshaping treatment approaches in diabetes and cardiovascular disease.

Post GSK, he has continued to hold senior leadership roles, most recently as Chief Operating Officer at HilleVax, where he prepared the company for Phase 3 development and commercialization of its norovirus vaccine platform.

At Denteric, he applies this same expertise in strategy, execution and team leadership to advance its pipeline.

MBA St. Joseph’s University (Philadelphia), BSc (Accounting) Queen’s University Belfast, Certificate in Executive Leadership Wharton School, University of Pennsylvania.

Laureate Professor Eric Reynolds AO is a world recognised expert in the field of Porphyromonas ginigvalis research.  Chief Executive Officer of the Centre for Oral Health at Melbourne Dental School at the University of Melbourne, Eric is a former Head of the Melbourne Dental School and past President of the International Association of Dental Research (IADR).  He has lectured and published extensively and has chaired and participated in a wide range of professional committees and panels.  

Eric was appointed an Officer of the Order of Australia for his service to community dental health in 2005.  He has also been awarded the Clunies Ross National Science and Technology award in 2002 and the Victoria Prize for Science in 2005.  In 2011 he was awarded the Distinguished Scientist Award by the IADR, and in 2015 the Leach Medal for research excellence and the Global Health Impact Award from the University of Melbourne.  

In 2016 he received the Award of Merit from the Australian Dental Association and in 2017 he received the Prime Minister’s Prize for Innovation.  In 2019 he was elected Vice-President of the International Association for Dental Research. 

Prof Chapple has published over 240 research papers in the peer reviewed scientific literature, and is the clinical lead for a hospital regional specialist periodontal service (referral base of 6-million).  Prof Chapple was President of the International Association for Dental Research (IADR) Periodontal Research Group (PRG-2006-7), Treasurer (2007-2013) and Secretary General (2016-2019) of the European Federation of Periodontology (EFP) and is currently Treasurer of the UK Oral and Dental Research Trust.

Prof Curtis works in Centre for Host-Microbiome Interactions at Kings College. Widely recognised for his research into the P.gingivalis keystone hypothesis, his research focuses on the oral microbiome, maintenance of health and oral/systemic disease and virulence determinants (gingipains) of oral bacteria.

Dr. Potempa’s investigations are focused on gingipains – the proteolytic enzymes of bacterial pathogens that play important roles in the deregulation of a number of physiological pathways and evasion of host immunity.  His work also focuses on the link between periodontitis and systemic disease. Jan holds a position as Professor and Academic Scholar at university of Louisville and is the Head of Microbiology at Jagiellonian University in Poland

Internationally recognized for his research in the epidemiology of periodontal diseases, the assessment of microbial and host-derived risk factors, the pathobiology of periodontitis and its role as a general health stressor in atherosclerosis and pregnancy complications.  Past President of IADR Research Group

Head of Internationalization in Dentistry and Professor of Inflammation Research (Periodontics). Elected Vice President of Microbiology/Immunology Group of the International Association for Dental Research (IADR).